A Rising Star in Sports Medicine: Tianxing Medical Rushes to IPO on Hong Kong Stock Exchange

On September 12, 2025, news from the financial sector revealed that Beijing Tianxing Medical Co., Ltd. (referred to as "Tianxing Medical") has submitted its prospectus to the Hong Kong Stock Exchange, intending to list on the main board. This innovative medical device company, which focuses on comprehensive clinical solutions in sports medicine, had previously planned to list on the A-share Sci-Tech Innovation Board, but ultimately withdrew its application due to market conditions. Now, shifting to the Hong Kong stock market, what does the future hold for Tianxing Medical? Let us explore together.

Leader in the field of sports medicine equipment

Tianxing Medical was established in 2017 and quickly established a foothold in the field of sports medicine with its four major patented technology platforms—biomaterials, imaging dynamics, smart healthcare, and tissue engineering. The company offers comprehensive treatment solutions for major joints including shoulder, knee, hip, ankle, elbow, and wrist, covering 52 products such as implants, active devices, and related consumables.

As of mid-August 2025, Tianxing Medical has owned 20 types of Class III medical devices, with several products being unique in the domestic market. The company's products have entered over 3,000 hospitals, including more than 1,000 tertiary hospitals, with cumulative sales exceeding 1.5 million units. It is worth mentioning that Tianxing Medical is also among the first batch of companies in China to develop an AI exercise prescription rehabilitation intelligent system.

Impressive Performance but There Are Concerns

Financial data shows that Tianxing Medical has seen steady growth in both revenue and profit in recent years. In 2024, the company's revenue reached 327 million RMB, with a net profit of 95 million RMB and a gross margin of 69.6%. However, a closer examination of its revenue structure reveals potential risks: implant products contributed over 70% of the revenue, and these products are facing the impact of centralized procurement policies.

In the face of this challenge, Tianxing Medical candidly stated in its prospectus that the inclusion of some implant products in the volume-based procurement plan may lead to a decrease in sales prices. If the growth in sales cannot compensate for the impact of price reductions, or if internal cost control measures fail to be effective, the company's performance may be affected.

Overseas markets become new growth points

It is worth noting that Tianxing Medical's overseas business is experiencing explosive growth. In the first five months before 2025, the company's overseas revenue surged by 370% year-on-year, accounting for 18.4% of total revenue. Currently, Tianxing Medical has obtained regulatory approvals and registration certificates for over 200 types of medical devices in more than 50 countries and regions, including Europe, Southeast Asia, the Middle East, and Latin America.

This listing in Hong Kong is expected to provide new momentum for Tianxing Medical's globalization strategy. The company plans to use the raised funds to expand production capacity, enhance efficiency, support research and development activities, and strengthen commercialization and marketing efforts.

Outlook

As the global sports medicine market expands at an annual rate of 6.5%, it is expected to reach a scale of 8.8 billion dollars by 2030. Against this backdrop, Tianxing Medical is likely to become an important reference for investors observing the valuation levels of leading companies in this sub-sector. However, whether it can successfully complete its listing on the Hong Kong stock market will be a key factor determining the future development of Tianxing Medical.

Overall, Tianxing Medical, with its professional advantages and innovative capabilities in the field of sports medicine, demonstrates good development potential. However, the company also faces challenges such as a single revenue structure and policy risks. Investors should cautiously assess the related risks while paying attention to its listing progress.